For instance, in prostate cancer bone metastases CTLA-4 is highly evident but infiltrating T cells are scarce; therefore, anti-CTLA-4 (ipilimumab) is one such drug strategy that is being used to revitalize immune cell attraction to the tumor. This evidence concerns the gene CTLA4 and prostate carcinoma.